118 related articles for article (PubMed ID: 30830506)
21. Oral Squamous Cell Carcinoma Cells with Acquired Resistance to Erlotinib Are Sensitive to Anti-Cancer Effect of Quercetin via Pyruvate Kinase M2 (PKM2).
Chan CY; Hong SC; Chang CM; Chen YH; Liao PC; Huang CY
Cells; 2023 Jan; 12(1):. PubMed ID: 36611972
[TBL] [Abstract][Full Text] [Related]
22. YM155 sensitizes non-small cell lung cancer cells to EGFR-tyrosine kinase inhibitors through the mechanism of autophagy induction.
Dai CH; Shu Y; Chen P; Wu JN; Zhu LH; Yuan RX; Long WG; Zhu YM; Li J
Biochim Biophys Acta Mol Basis Dis; 2018 Dec; 1864(12):3786-3798. PubMed ID: 30315932
[TBL] [Abstract][Full Text] [Related]
23. YAP promotes erlotinib resistance in human non-small cell lung cancer cells.
Hsu PC; You B; Yang YL; Zhang WQ; Wang YC; Xu Z; Dai Y; Liu S; Yang CT; Li H; Hu B; Jablons DM; You L
Oncotarget; 2016 Aug; 7(32):51922-51933. PubMed ID: 27409162
[TBL] [Abstract][Full Text] [Related]
24. [Molecular mechanism of erlotinib resistance in epidermal growth factor receptor mutant non-small cell lung cancer cell line H1650].
Han R; Wang X; Zhong D; Zhao J; Chen Z; Sun L; Wang J; Zhang J
Zhongguo Fei Ai Za Zhi; 2012 Dec; 15(12):689-93. PubMed ID: 23249714
[TBL] [Abstract][Full Text] [Related]
25. JAK2 inhibitor TG101348 overcomes erlotinib-resistance in non-small cell lung carcinoma cells with mutated EGF receptor.
Zhang FQ; Yang WT; Duan SZ; Xia YC; Zhu RY; Chen YB
Oncotarget; 2015 Jun; 6(16):14329-43. PubMed ID: 25869210
[TBL] [Abstract][Full Text] [Related]
26. The Role of Self-Nanoemulsifying Drug Delivery Systems of CDODA-Me in Sensitizing Erlotinib-Resistant Non-Small Cell Lung Cancer.
Nottingham E; Sekar V; Mondal A; Safe S; Rishi AK; Singh M
J Pharm Sci; 2020 Jun; 109(6):1867-1882. PubMed ID: 31954111
[TBL] [Abstract][Full Text] [Related]
27. Inhibition of JAK1/2 can overcome EGFR-TKI resistance in human NSCLC.
Kim DM; Kim MJ; Moon JH; Lee EY; Hong JK; Lee S; Koh DI; Ryu YS; Kim SM; Jung SA; Shin JS; Kim J; Park YS; Hong SW; Lee SH; Jung J; Park SS; Kim DY; Kim EH; Jeong HR; Gong JH; Kim J; Chan Kim S; Yu HN; Ki SY; Kim TW; Jin DH
Biochem Biophys Res Commun; 2020 Jun; 527(1):305-310. PubMed ID: 32446385
[TBL] [Abstract][Full Text] [Related]
28.
Hu C; Zhou A; Hu X; Xiang Y; Huang M; Huang J; Yang D; Tang Y
Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36362025
[TBL] [Abstract][Full Text] [Related]
29. Nicotine induces resistance to erlotinib via cross-talk between α 1 nAChR and EGFR in the non-small cell lung cancer xenograft model.
Li H; Wang S; Takayama K; Harada T; Okamoto I; Iwama E; Fujii A; Ota K; Hidaka N; Kawano Y; Nakanishi Y
Lung Cancer; 2015 Apr; 88(1):1-8. PubMed ID: 25670150
[TBL] [Abstract][Full Text] [Related]
30. Ramucirumab plus erlotinib versus placebo plus erlotinib in previously untreated EGFR-mutated metastatic non-small-cell lung cancer (RELAY): exploratory analysis of next-generation sequencing results.
Garon EB; Reck M; Nishio K; Heymach JV; Nishio M; Novello S; Paz-Ares L; Popat S; Aix SP; Graham H; Butts BD; Visseren-Grul C; Nakagawa K;
ESMO Open; 2023 Aug; 8(4):101580. PubMed ID: 37390764
[TBL] [Abstract][Full Text] [Related]
31. Polo-like kinase 1 inhibition diminishes acquired resistance to epidermal growth factor receptor inhibition in non-small cell lung cancer with T790M mutations.
Wang Y; Singh R; Wang L; Nilsson M; Goonatilake R; Tong P; Li L; Giri U; Villalobos P; Mino B; Rodriguez-Canales J; Wistuba I; Wang J; Heymach JV; Johnson FM
Oncotarget; 2016 Jul; 7(30):47998-48010. PubMed ID: 27384992
[TBL] [Abstract][Full Text] [Related]
32. Enhancement of Pancreatic Cancer Therapy Efficacy by Type-1 Matrix Metalloproteinase-Functionalized Nanoparticles for the Selective Delivery of Gemcitabine and Erlotinib.
Yin N; Yu H; Zhang X; Lv X
Drug Des Devel Ther; 2020; 14():4465-4475. PubMed ID: 33122890
[TBL] [Abstract][Full Text] [Related]
33. The repression and reciprocal interaction of DNA methyltransferase 1 and specificity protein 1 contributes to the inhibition of MET expression by the combination of Chinese herbal medicine FZKA decoction and erlotinib.
Zheng F; Zhao Y; Li X; Tang Q; Wu J; Wu W; Hann SS
J Ethnopharmacol; 2019 Jul; 239():111928. PubMed ID: 31077779
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of mitochondrial glutaminase activity reverses acquired erlotinib resistance in non-small cell lung cancer.
Xie C; Jin J; Bao X; Zhan WH; Han TY; Gan M; Zhang C; Wang J
Oncotarget; 2016 Jan; 7(1):610-21. PubMed ID: 26575584
[TBL] [Abstract][Full Text] [Related]
35. Polyphyllin I Overcomes EMT-Associated Resistance to Erlotinib in Lung Cancer Cells via IL-6/STAT3 Pathway Inhibition.
Lou W; Chen Y; Zhu KY; Deng H; Wu T; Wang J
Biol Pharm Bull; 2017 Aug; 40(8):1306-1313. PubMed ID: 28515374
[TBL] [Abstract][Full Text] [Related]
36. UPLC-ESI-MS/MS study of the effect of green tea extract on the oral bioavailability of erlotinib and lapatinib in rats: Potential risk of pharmacokinetic interaction.
Maher HM; Alzoman NZ; Shehata SM; Abahussain AO
J Chromatogr B Analyt Technol Biomed Life Sci; 2017 Apr; 1049-1050():30-40. PubMed ID: 28260629
[TBL] [Abstract][Full Text] [Related]
37. Development and in vitro evaluation of core-shell type lipid-polymer hybrid nanoparticles for the delivery of erlotinib in non-small cell lung cancer.
Mandal B; Mittal NK; Balabathula P; Thoma LA; Wood GC
Eur J Pharm Sci; 2016 Jan; 81():162-71. PubMed ID: 26517962
[TBL] [Abstract][Full Text] [Related]
38. Nanoparticulation improves bioavailability of Erlotinib.
Yang KM; Shin IC; Park JW; Kim KS; Kim DK; Park K; Kim K
Drug Dev Ind Pharm; 2017 Sep; 43(9):1557-1565. PubMed ID: 28554216
[TBL] [Abstract][Full Text] [Related]
39. Luteolin is effective in the non-small cell lung cancer model with L858R/T790M EGF receptor mutation and erlotinib resistance.
Hong Z; Cao X; Li N; Zhang Y; Lan L; Zhou Y; Pan X; Shen L; Yin Z; Luo L
Br J Pharmacol; 2014 Jun; 171(11):2842-53. PubMed ID: 24471765
[TBL] [Abstract][Full Text] [Related]
40. Down-regulation of miR-214 reverses erlotinib resistance in non-small-cell lung cancer through up-regulating LHX6 expression.
Liao J; Lin J; Lin D; Zou C; Kurata J; Lin R; He Z; Su Y
Sci Rep; 2017 Apr; 7(1):781. PubMed ID: 28396596
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
